Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells

Yong Liu, Maurizio Chiriva-Internati, Changxuan You, Rongcheng Luo, Hong You, C. Krishna Prasad, Fabio Grizzi, Everardo Cobos, Vicki Klimberg, Helen Kay, Jawahar L. Mehta, Paul L. Hermonat

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Antigen-targeted immunotherapy is an emerging treatment for breast cancer. However, useful breast cancer antigens are only found in a subset of cancer patients. BA46, also known as lactadherin, is a membrane-associated glycoprotein that is expressed in most breast cancer cells but not in general hematopoietic cell populations. Moreover, it is much more difficult to generate CTLs against self-antigens. We wished to determine if the use of recombinant adeno-associated virus (rAAV) type 2 vectors for gene-loading of dendritic cells (DCs) could generate rapid, effective cytotoxic T lymphocytes (CTLS) against BA46. We were able to demonstrate that AAV/BA46/Neo-loading of DCs resulted in: (1) BA46 expression in DCs, (2) chromosomal integration of the AAV/BA46/Neo vector within DCs, (3) strong, rapid BA46-specific, MHC class I-restricted CTLs in only 1 week, (4) T-cell populations with significant interferon-γ (IFN-γ) expression but low IL-4 expression, (5) high CD80 and CD86 expression in DCs, and (6) high CD8:CD4 and CD8:CD56 T cell ratios. These data suggest that rAAV-loading of DCs may be useful for immunotherapeutic protocols against self-antigens in addition to viral antigens and that the BA46 antigen is potentially appropriate for cell-mediated immunotherapeutic protocols addressing ductal breast cancer.

Original languageEnglish (US)
Pages (from-to)304-312
Number of pages9
JournalCancer Gene Therapy
Volume12
Issue number3
DOIs
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

Dependovirus
Milk Proteins
Cytotoxic T-Lymphocytes
Dendritic Cells
Breast Neoplasms
Antigens
Genes
Autoantigens
T-Lymphocytes
Viral Antigens
Membrane Glycoproteins
Interleukin-4
Immunotherapy
Interferons
Population
Neoplasms

Keywords

  • Adeno-associated virus
  • BA46
  • Breast cancer
  • Cytotoxic T lymphocyte
  • Dendritic cell
  • Immunology

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells. / Liu, Yong; Chiriva-Internati, Maurizio; You, Changxuan; Luo, Rongcheng; You, Hong; Prasad, C. Krishna; Grizzi, Fabio; Cobos, Everardo; Klimberg, Vicki; Kay, Helen; Mehta, Jawahar L.; Hermonat, Paul L.

In: Cancer Gene Therapy, Vol. 12, No. 3, 03.2005, p. 304-312.

Research output: Contribution to journalArticle

Liu, Yong ; Chiriva-Internati, Maurizio ; You, Changxuan ; Luo, Rongcheng ; You, Hong ; Prasad, C. Krishna ; Grizzi, Fabio ; Cobos, Everardo ; Klimberg, Vicki ; Kay, Helen ; Mehta, Jawahar L. ; Hermonat, Paul L. / Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells. In: Cancer Gene Therapy. 2005 ; Vol. 12, No. 3. pp. 304-312.
@article{d0fde8aebc994f29a259dbc092a83861,
title = "Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells",
abstract = "Antigen-targeted immunotherapy is an emerging treatment for breast cancer. However, useful breast cancer antigens are only found in a subset of cancer patients. BA46, also known as lactadherin, is a membrane-associated glycoprotein that is expressed in most breast cancer cells but not in general hematopoietic cell populations. Moreover, it is much more difficult to generate CTLs against self-antigens. We wished to determine if the use of recombinant adeno-associated virus (rAAV) type 2 vectors for gene-loading of dendritic cells (DCs) could generate rapid, effective cytotoxic T lymphocytes (CTLS) against BA46. We were able to demonstrate that AAV/BA46/Neo-loading of DCs resulted in: (1) BA46 expression in DCs, (2) chromosomal integration of the AAV/BA46/Neo vector within DCs, (3) strong, rapid BA46-specific, MHC class I-restricted CTLs in only 1 week, (4) T-cell populations with significant interferon-γ (IFN-γ) expression but low IL-4 expression, (5) high CD80 and CD86 expression in DCs, and (6) high CD8:CD4 and CD8:CD56 T cell ratios. These data suggest that rAAV-loading of DCs may be useful for immunotherapeutic protocols against self-antigens in addition to viral antigens and that the BA46 antigen is potentially appropriate for cell-mediated immunotherapeutic protocols addressing ductal breast cancer.",
keywords = "Adeno-associated virus, BA46, Breast cancer, Cytotoxic T lymphocyte, Dendritic cell, Immunology",
author = "Yong Liu and Maurizio Chiriva-Internati and Changxuan You and Rongcheng Luo and Hong You and Prasad, {C. Krishna} and Fabio Grizzi and Everardo Cobos and Vicki Klimberg and Helen Kay and Mehta, {Jawahar L.} and Hermonat, {Paul L.}",
year = "2005",
month = "3",
doi = "10.1038/sj.cgt.7700785",
language = "English (US)",
volume = "12",
pages = "304--312",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells

AU - Liu, Yong

AU - Chiriva-Internati, Maurizio

AU - You, Changxuan

AU - Luo, Rongcheng

AU - You, Hong

AU - Prasad, C. Krishna

AU - Grizzi, Fabio

AU - Cobos, Everardo

AU - Klimberg, Vicki

AU - Kay, Helen

AU - Mehta, Jawahar L.

AU - Hermonat, Paul L.

PY - 2005/3

Y1 - 2005/3

N2 - Antigen-targeted immunotherapy is an emerging treatment for breast cancer. However, useful breast cancer antigens are only found in a subset of cancer patients. BA46, also known as lactadherin, is a membrane-associated glycoprotein that is expressed in most breast cancer cells but not in general hematopoietic cell populations. Moreover, it is much more difficult to generate CTLs against self-antigens. We wished to determine if the use of recombinant adeno-associated virus (rAAV) type 2 vectors for gene-loading of dendritic cells (DCs) could generate rapid, effective cytotoxic T lymphocytes (CTLS) against BA46. We were able to demonstrate that AAV/BA46/Neo-loading of DCs resulted in: (1) BA46 expression in DCs, (2) chromosomal integration of the AAV/BA46/Neo vector within DCs, (3) strong, rapid BA46-specific, MHC class I-restricted CTLs in only 1 week, (4) T-cell populations with significant interferon-γ (IFN-γ) expression but low IL-4 expression, (5) high CD80 and CD86 expression in DCs, and (6) high CD8:CD4 and CD8:CD56 T cell ratios. These data suggest that rAAV-loading of DCs may be useful for immunotherapeutic protocols against self-antigens in addition to viral antigens and that the BA46 antigen is potentially appropriate for cell-mediated immunotherapeutic protocols addressing ductal breast cancer.

AB - Antigen-targeted immunotherapy is an emerging treatment for breast cancer. However, useful breast cancer antigens are only found in a subset of cancer patients. BA46, also known as lactadherin, is a membrane-associated glycoprotein that is expressed in most breast cancer cells but not in general hematopoietic cell populations. Moreover, it is much more difficult to generate CTLs against self-antigens. We wished to determine if the use of recombinant adeno-associated virus (rAAV) type 2 vectors for gene-loading of dendritic cells (DCs) could generate rapid, effective cytotoxic T lymphocytes (CTLS) against BA46. We were able to demonstrate that AAV/BA46/Neo-loading of DCs resulted in: (1) BA46 expression in DCs, (2) chromosomal integration of the AAV/BA46/Neo vector within DCs, (3) strong, rapid BA46-specific, MHC class I-restricted CTLs in only 1 week, (4) T-cell populations with significant interferon-γ (IFN-γ) expression but low IL-4 expression, (5) high CD80 and CD86 expression in DCs, and (6) high CD8:CD4 and CD8:CD56 T cell ratios. These data suggest that rAAV-loading of DCs may be useful for immunotherapeutic protocols against self-antigens in addition to viral antigens and that the BA46 antigen is potentially appropriate for cell-mediated immunotherapeutic protocols addressing ductal breast cancer.

KW - Adeno-associated virus

KW - BA46

KW - Breast cancer

KW - Cytotoxic T lymphocyte

KW - Dendritic cell

KW - Immunology

UR - http://www.scopus.com/inward/record.url?scp=20044366384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044366384&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700785

DO - 10.1038/sj.cgt.7700785

M3 - Article

VL - 12

SP - 304

EP - 312

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 3

ER -